Chiglitazar/Metformin
AssetAlso Chiglitazar/Metformin extended-release tablets
Dual-action combination therapy improving insulin sensitivity and glucose homeostasis via pan-PPAR activation and hepatic gluconeogenesis inhibition.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- AMPK signalling
- 1
- Indication
- 1,357
- Trials
- 1
- Developer
Indications
1Type 2 diabetes
Phase 3, Completed, NCT04807348, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains7
- Owner and partners1
- Trials1,357
- Evidence for its targets7
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.